Pavmed Inc. · NASDAQ:PAVM
Pavmed — Investor Presentation (October 2017)
29 slides from Pavmed's investor presentation, Oct 2, 2017
Slide 1: PAVmed: Innovating at the Speed of Life
¥« PAVmed INNOVATING AT THE SPEED OF LIFE™ NASDAQ: PAVM LISHAN AKLOG MD, CHA/RMAN & CEO DENNIS MCGRATH, Executive VP &CFO XK PAVmed
Slide 2: Disclaimers
Disclaimers % This presentation contains certain forward-looking statements that involve risks and uncertainties. + Actual results and events may differ significantly from results and events discussed in forward-looking statements. + Factors that might cause or contribute to such differences include
Slide 3: Highly Differentiated, Multi-Product Medical Device Company
S<PAVmed INNOVATING AT THE SPEED OF LIFE HIGHLY DIFFERENTIATED, MULTI-PRODUCT MEDICAL DEVICE COMPANY x Nasdaq-listed: PAVM ¥% High-margin, high-impact single-use interventional or acute care products ¥ Broad spectrum of clinical conditions and specialty call points
Slide 4: Strong Track Record of Innovation and Value Creation
Strong Track Record of Innovation and Value Creation Speed to Market Capital Efficiency Multiple Pathways to Commercialization Oe Ug . {00 nm Two Near-term Milestones Total Addressable Market over $3B
Slide 5: Key Recent Developments
Key Recent Developments % Balance sheet strengthened * $8.5 million in raised in 2017 from seasoned healthcare investors = Adequate capital into Q2 2018 through key regulatory milestones % Steady progress towards lead product milestones = PortlO under FDA review = CarpX FDA submission imminent = Dis
Slide 6: Capital Structure
Capital Structure PAVmed, Inc (Nasdaq:PAVM, PAVMW) Exercise/ Common Stock Insider Conversion Price Equivalents Outstanding Ownership (Weighted Avg.) (Treasury) Common Stock 13,331,211 64% 13,331,211 Preferred Stock 560,822 0% $4.80 649,034 Warrants 13,840,533 61% $4.11 4,133,265 Options 1,974,924 $5
Slide 7: PAVmed's Founders
PAVmed’s Founders LISHAN HARVARD AKLOG Aten MD , oun OU & CEO a ee University of micHac Rp) Beritinbtice GLENNON . ae STORZ stryker CHAIRMAN ORIGIN meDsvstems BRIAN BOSTON DEGUZMAN oS MD Georgetown CHIEF MEDICAL Dy. Orricer Hospital XK PAVmed As fal Mount S$ Disnity Health GUIDANT &}medtronic “accel
Slide 8: PAVmed's History
PAVmed’s History P eseuen =e PAVmed INNOVATING AT THE SPEED OF LIFE™ NASDAQ IPO COMPLETED Se Ravine: PAVMED FOUNDED FIRST FDA 510K SUBMISSION INITIAL PIPELINE OF SIXTH PRODUCT LICENSED FIVE INNOVATIONS FROM ACADEMIC CONSORTIUM op pe
Slide 9: Business Model
Business Model MULTI-PRODUCT PIPELINE RISK MITIGATION + Non-binary success COMMERCIAL OPPORTUNITY ATTRACTIVE MARKET + Unmet clinical need KEY BUSINESS PROCESSES CAPITAL EFFICIENCY & SPEED TO MARKET + Outsourced best-in-class process experts + Light infrastructure, low fixed costs + Shortest path to
Slide 10: Lead Products
Lead Products PRODU PORTIO Implantable Intraosseous Vascular Access Device i CARPX Percutaneous Device to treat Carpal Tunnel Syndrome DISAPPEAR Antibiotic-Eluting i Resorbable Ear Tubes MARKET OPPORTUNITY >$750M >$1B REGULATORY PATH 510(k) (possibly de novo) 510(k) 510(k)
Slide 11: Multiple Pathways to Commercialization
Multiple Pathways to Commercialization Tailored to Maximize Value Creation TARGETED INITIAL COMMERCIALIZATION + Key Opinion Leaders + Independent Distributors CORPORATE CORPORATE FULL SELF ACQUIRER PARTNER COMMERCIALIZATION + Asset sale to strategic | - Sales & distribution - Hybrid sales channel +
Slide 12: PortIO
PortlO /mplantable Intraosseous Vascular Access Devices XK PAVmed
Slide 13: Vascular Access Devices
Vascular Access Devices Used to deliver medications, fluids, nutrition and other substances } ER | INPATIENT <24 Hours | <7-10 days <6 weeks <1 year Intraosseous Central Venous Tunneled Central Device Catheter (CVC) Venous Catheter Peripherally Inserted Central Implantable Port Catheter (PICC) (Port
Slide 14: Vascular Access Devices: Unmet Clinical Need
Vascular Access Devices UNMET CLINICAL NEED — CURRENT DEVICE LIMITATIONS Limitations driven by intravascular component + Up to 35% + Clot-busting medications or a repeat procedure Up to 10% 50% life-threatening bloodstream infections + >10% of patients + Surgical insertion & + Pacemaker/Defibrillato
Slide 15: Intraosseous Vascular Access
Intraosseous Vascular Access ¥ Infusion directly into the Bone Marrow Cavity Decades of experience = Trauma, esp. military = Pediatric emergencies hosts = Bioequivalent to Device intravenous route XK PAVmed
Slide 16: PortIO: Implantable Intraosseous Port
PortlO — Implantable Intraosseous Port % Components * Titanium body = Internal conical needle guide Implantable * Hollow titanium bone screw ea Huber Access Needle * Silicone septum % Implanted into bone * Tip positioned in bone marrow No Intravascular Component alow “Tienam “Sitcone ¥& Functionally
Slide 17: PortIO: Implantable Intraosseous Port
PortlO — Implantable Intraosseous Port Market opportunity and regulatory strategy function of implant duration Duration <24 Hours Market Size ~$150M Advantages + Near limitless access sites + Less prone to dislodgement Duration <T-10 days Market Size ~$200M (Poor vein pts) Advantages + Near limitles
Slide 18: PortIO: Current Status
PortlO — Current Status % Under FDA Review * 510(k) application for 24 hour indication = Teleflex EZIO as predicate = Adjusted to address FDA substantial equivalence = Expect response soon = May need to convert to de novo 510(k) x Commercialization Strategy established = Initial launch using indepen
Slide 19: CarpX
CarpX Percutaneous Device to Treat Carpal Tunnel Syndrome
Slide 20: Carpal Tunnel Syndrome
Carpal Tunnel Syndrome CLINICAL OVERVIEW % Incidence = Over 600,000 U.S. procedures annually * Up to 1.5 million with symptoms who “suffer in silence” 3 Mechanism * Inflammation and scarring of transverse carpal ligament = Entrapment of the median nerve = hand pain, numbness and weakness XK PAVmed
Slide 21: Carpal Tunnel Syndrome
Carpal Tunnel Syndrome MarKET OPPORTUNITY 5 600,000 current surgeries x $1,500 minimum ASP = ~$1 Billion 3¢ Additional 1.5M “silent sufferers” who choose to defer surgery UNMET CLINICAL NEED — CURRENT LIMITATIONS TRADITIONAL CARPAL TUNNEL ENDOSCOPIC SURGERY SURGERY IS INVASIVE IS LESS EFFECTIVE +Up
Slide 22: CarpX: The PAVmed Solution
CarpX - The PAVmed Solution PERCUTANEOUS DEVICE To TREAT CARPAL TUNNEL SYNDROME Components = Balloon catheter « Integrated bipolar RF cutting electrodes = Control handle xKey Features = Single-use device = Connects to standard electrosurgical generator = Balloon provides anatomic separation = Pushes
Slide 23: CarpX in Action
CarpX in Action Kav e Balloon inflated ~ Device inserted and positioned Balloon inflated (sideview) Transverse carpal ligament cut
Slide 24: CarpX in Action
CarpX in Action
Slide 25: CarpX in Action
CarpX in Action
Slide 26: CarpX: The PAVmed Solution
CarpX - The PAVmed Solution % Truly percutaneous 38 Shift from OR to interventional lab 5 No surgical incision or dissection % Shorten procedural times 3€ Less pain, scarring and recovery %€ Shorten recovery time and return time to work FEWER COMPLICATIONS EXPANDED MARKET 5€ Better nerve protection
Slide 27: CarpX: Current Status
PortlO — Current Status % FDA Submission Imminent = Testing nearly completed = 510(k) application being drafted = Smith & Nephew carpal release system as predicate % Commercialization Strategy established = Initial launch using independent distributors = Hand Surgery/Interventional Radiology Key Opi
Slide 28: Growth Strategy
Growth Strategy x Raise permanent capital x Advance products to commercialization = PortlO — late Q4-2017 (Q2-2018 if denovo) FDA clearance = CarpX — early Q4 FDA submission = DisappEAR — Q3 2018 FDA submission = Accelerate R&D products into commercialization channel x Explore M&A acquisition target
Slide 29: Strong Track Record of Innovation and Value Creation
Strong Track Record of Innovation and Value Creation Speed to Market Capital Efficiency Multiple Pathways to Commercialization Oe Ug . {00 nm Two Near-term Milestones Total Addressable Market over $3B